GlassScriptPhysician profile
Joel A Holiner
NPI 1639174246
$947,668.55
in general payments reported to CMS, 2019-2025
41 companies · $216K in 2025
The $216K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51K · 2020: $48K · 2021: $84K · 2022: $123K · 2023: $200K · 2024: $228K · 2025: $216K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $388K · Consulting Fee: $82K · Honoraria: $79K · Travel and Lodging: $54K · Food and Beverage: $30K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $11K · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $388,000.63 |
| Consulting Fee | $82,141.00 |
| Honoraria | $78,926.00 |
| Travel and Lodging | $53,555.93 |
| Food and Beverage | $29,918.46 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,675.88 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $303,235.41 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $259,205.91 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Supernus Pharmaceuticals, INC. | $93,614.46 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $79,105.63 | 2023-2025 | Auvelity |
| Alkermes, INC. | $47,986.94 | 2019-2025 | Lybalvi, Aristada |
| Eisai INC. | $29,796.20 | 2020-2021 | |
| Tris Pharma INC | $24,470.29 | 2019-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Vanda Pharmaceuticals INC. | $17,484.62 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $15,617.52 | 2019-2025 | Ingrezza |
| Noven Pharmaceuticals, INC. | $9,929.96 | 2023-2024 | Xelstrym |
| Corium, LLC | $9,697.90 | 2022-2025 | Azstarys, Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $8,856.76 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $8,113.18 | 2022-2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $7,957.53 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $7,770.85 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $7,520.37 | 2025 | |
| Janssen Pharmaceuticals, INC | $5,044.69 | 2019-2025 | Spravato, Invega Sustenna |
| Indivior INC. | $2,224.03 | 2019-2024 | Perseris |
| Noven Therapeutics, LLC | $2,135.66 | 2025 | Xelstrym, Secuado |
| Abbvie INC. | $2,090.90 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $1,750.73 | 2019-2022 | |
| Neuronetics, INC. | $755.72 | 2019-2022 | |
| Allergan, INC. | $733.95 | 2019-2020 | |
| Lundbeck LLC | $611.47 | 2020-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Ironshore Pharmaceuticals INC. | $279.38 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $267.00 | 2019-2022 | |
| Livanova USA, INC. | $219.38 | 2019-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Janssen Scientific Affairs, LLC | $210.32 | 2019-2020 | |
| Neos Therapeutics, LP | $189.49 | 2019-2025 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $159.26 | 2025 | Jornay Pm |
| Sumitomo Pharma America, INC. | $130.77 | 2023 | |
| Merck Sharp & Dohme LLC | $113.97 | 2019-2023 | Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.73 | 2023 | |
| Kaleo, INC. | $67.71 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $55.01 | 2019 | |
| Almatica Pharma LLC | $39.94 | 2024 | Loreev Xr |
| Bausch Health US, LLC | $37.79 | 2024-2025 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $32.26 | 2020-2022 | |
| Orexo US, INC. | $20.22 | 2021 | |
| Tempus Ai, INC | $15.59 | 2024 | |
| Shire North American Group INC | $14.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Holiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.